Vnitr Lek 2022, 68(5):285-289 | DOI: 10.36290/vnl.2022.061

Early diagnosis of systemic scleroderma

Adéla Skoumalová1, Pavel Horák1, Zuzana Heřmanová2, Jakub Videman1, Andrea Smržová1, Viktor Palla3
1 III. interní klinika - nefrologická, revmatologická a endokrinologická, FN a LF UP Olomouc
2 Ústav imunologie, FN a LF UP Olomouc
3 Klinika chorob kožních a pohlavních, FN a LF UP Olomouc

Systemic scleroderma (SSc) is a systemic immune-mediated connective tissue disease characterized by fibroproductive changes in connective tissue and microvascular disorders. The disease affects the skin, musculoskeletal system and internal organs. It is a disease with a significant rate of morbidity and mortality, significantly worsening the quality of life of patients. Early initiation of therapy is necessary to prevent disease progression. This review article discusses the current possibilities of early diagnosis of systemic scleroderma.

Keywords: diagnostics, early forms of scleroderma, systemic scleroderma.

Accepted: August 4, 2022; Published: August 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skoumalová A, Horák P, Heřmanová Z, Videman J, Smržová A, Palla V. Early diagnosis of systemic scleroderma. Vnitr Lek. 2022;68(5):285-289. doi: 10.36290/vnl.2022.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Assassi S, Del Junco D, Sutter K et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheumatism. 2009;61:1403-1411. Go to original source... Go to PubMed...
    2. Bečvář R, Soukup T, Štork J et al. Doporučení České revmatologické společnosti pro diagnostiku systémové sklerodermie. Česká Revmatologie. 2014;22, č. 2.
    3. Gemma Lepri, Silvia Bellando Randone, Marco Matucci Cerinic et al. Early diagnosis of systemic sclerosis, where do we stand today?, Expert Review of Clinical Immunology. 2022, 18:1,1-3. Available from DOI: < https://doi.org/10.1080/1744666X.2022.2015327> Go to original source... Go to PubMed...
    4. Ariane L. Herrick, Fredrick M. Wigley. Raynaud's phenomenon, Best Practice & Research Clinical Rheumatology. 2020, Volume 34, Issue 1, 1521-6942. Go to original source... Go to PubMed...
    5. Soukup T et al. Systémová sklerodermie v roce 2017. Vnitř Lék 2018; 64(2):146-154. Go to original source... Go to PubMed...
    6. Poudel DR, Jayakumar D, Danve A et al. Determinants of mortality in systemic sclerosis: a focused review. Rheumatology International, 2017;38(10),1847-1858. Go to original source... Go to PubMed...
    7. Horák P, Žurková M, Skoumalová A et al. Rozšiřující se možnosti léčby intersticiálního plicního postižení u systémových onemocnění pojiva. Remedia 2022;32:12-20.
    8. Roofeh D, Lescoat A, Khanna D. Treatment for systemic sclerosis‑associated interstitial lung disease. Current Opinion in Rheumatology, 2021; 33(3),240-248. Available from DOI: https://doi.org/10.1097/bor.0000000000000795 Go to original source... Go to PubMed...
    9. Perelas A, Silver RM, Arrossi AV et al. Systemic sclerosis‑associated interstitial lung disease. Lancet Respir Med. 2020; 8(3):304-320. Available from DOI: Go to original source... Go to PubMed...
    10. Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012;24(6):669-676. Available from DOI: Go to original source... Go to PubMed...
    11. Woodworth TG, Suliman YA., LW, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nature Reviews Nephrology. 2016;12(11),678-691. Available from DOI: https://doi.org/10.1038/nrneph.2016.124 Go to original source... Go to PubMed...
    12. Adler S, Varisco P, Distler O et al. SAT0508 Ace‑inhibitors in arterial hypertension in ssc patients display a risk factor for scleroderma renal crisis - a eustar analysis. Ann Rheum Dis 2018; 77:1110. Go to original source...
    13. Frech TM, Mar D. Gastrointestinal and Hepatic Disease in Systemic Sclerosis. Rheum Dis Clin North Am. 2018;44(1):15-28. Available from DOI: Go to original source... Go to PubMed...
    14. Morrisroe KB, Nikpour M, Proudman SM. Musculoskeletal Manifestations of Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2015; 41(3),507-518. Available from DOI: Go to original source... Go to PubMed...
    15. Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involvement in systemic sclerosis. Best Practice & Research Clinical Rheumatology, 2008;22(2), 339-350. Available from DOI: Go to original source... Go to PubMed...
    16. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. Available from DOI: < https://doi.org/10.1016/S0140-6736(17)30933-9> Go to original source... Go to PubMed...
    17. van Den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum, DiS. 2013;72(11):1747-1755. Go to original source... Go to PubMed...
    18. Avouac J, Fransen J, Walker U et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Annals of the Rheumatic Diseases. 2010;70(3),476-481. Available from DOI: Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.